On April 27, 2026 Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, reported multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting being held in Chicago from May 29-June 2, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Company has two abstracts selected for oral presentation, including a 3-year landmark overall survival analysis from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) plus nivolumab in anti-PD-1 failed melanoma, and an oral presentation on the final safety, efficacy, and biomarker results from the Phase 1 first-in-human study of RP2 alone and combined with nivolumab in advanced solid tumors. Four additional posters for RP1 and RP2 will be presented.
Details for the presentations are as follows:
Oral data presentations
Abstract Title: A 3-year landmark overall survival analysis of RP1 plus nivolumab in patients with anti-PD-1-failed melanoma from the IGNYTE clinical trial.
Session Title: Rapid Oral Abstract Session – Melanoma/Skin Cancers
Presenter: Michael Wong, MD, PhD
Date: May 30, 2026, 5:30-5:36 pm CDT
Location: E451
Abstract #: 9518
Abstract Title: RP2 oncolytic immunotherapy alone and in combination with nivolumab (nivo) in patients with advanced solid tumors: Final safety, efficacy, and biomarker results from the phase 1 first-in-human (FIH) study.
Session Title: Oral Abstract Session – Developmental Therapeutics-Immunotherapy
Presenter: Joseph Sacco, PhD, MBChB
Date: May 31, 2026, 9:12-9:24 AM CDT
Location: Arie Crown Theater
Abstract #: 2504
Poster presentations
Abstract Title: Safety and feasibility of intratumoral injection of RP1 or RP2 oncolytic immunotherapies in visceral metastases.
Poster Session Title: Developmental Therapeutics-Immunotherapy
Presenter: Caroline Robert, MD, PhD
Date: May 30, 2026, 1:30-4:30 PM CDT
Location: Hall A, Poster 387
Abstract #: 2597
Abstract Title: A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor-naïve patients with metastatic uveal melanoma.
Poster Session Title: Melanoma/Skin Cancers
Presenter: Marlana Orloff, MD
Date: May 31, 2025, 9:00 AM-12:00 PM CDT
Location: Hall A, Poster 481a
Abstract #: TPS9598
Abstract Title: A randomized, controlled, multicenter, phase 3 study of RP1 (vusolimogene oderparepvec) combined with nivolumab vs physician’s choice of therapy in patients with advanced melanoma that has progressed on anti-PD-1 and anti-CTLA-4 therapy (IGNYTE-3).
Poster Session Title: Melanoma/Skin Cancers
Presenter: Yana Najjar, MD
Date: May 31, 2026, 9:00 AM-12:00 PM CDT
Location: Hall A, Poster 480b
Abstract #: TPS9597
Abstract Title: A multicenter, open-label study of RP2 oncolytic immunotherapy expressing anti-CTLA-4 combined with second-line atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC) or with first-line durvalumab in advanced biliary tract cancer (BTC).
Poster Session Title: Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary
Presenter: Richard Kim, MD
Date: May 30, 2026, 9:00 AM-12:00 PM CDT
Location: Hall A, Poster 230a
Abstract #: TPS4255
About RP1
RP1 (vusolimogene oderparepvec) is Replimune’s lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response.
About RP2
RP2 is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF. RP2 is intended to provide targeted and potent delivery of these proteins to the sites of immune response initiation in the tumor and draining lymph nodes, with the goal of focusing systemic-immune-based efficacy on tumors and limiting off-target toxicity.
(Press release, Replimune, APR 27, 2026, View Source [SID1234664803])